25 July 2018 - Just Published: PET and fMRI imaging on NLX-112 and NLX-101
2018-07-25 · Neurolixis SAS · original neurolixis.com ↗
An innovative brain imaging study combined Positron Emission Tomography (PET) and functional Magnetic Resonance Imaging (fMRI) to characterize the labeling and functional connectivity of NLX-112 and NLX-101 . Both compounds are highly selective for serotonin 5-HT1A receptors but exhibit preferential interaction (or 'biased agonism') at specific receptor sub-populations. NLX-112 is being developed for treatment of dyskinesia in Parkinson's disease , whereas NLX-101 is a candidate for treatment of Rett syndrome . The imaging study was carried out at the Lyon Neuroscience Research Center (France) by the team of Prof. Luc Zimmer , with whom Neurolixis has a long-standing collaboration. In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging. Vidal B, Fieux S, Redouté J, Villien M, Bonnefoi F, Le Bars D, Newman-Tancredi A, Costes N, Zimmer L. Neuropsychopharmacology . 2018 Jul 6. doi: 10.1038/s41386-018-0145-2. PMID: 30030540
The release as fetched from its publisher. neurolixis.com ↗